reports
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Michiel Declercq
- Wim Lewi
argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal M...
argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN) patients ADHERE+ data show durability of functional improvements with VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), which is FDA approved for use in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) June 25, 2024 – 4:30pm EDT Amsterdam, the Netherlands – argenx SE (Euro...
Progress on share buyback programme
Progress on share buyback programme Progress on share buyback programme ING announced today that, as part of our €2.5 billion share buyback programme announced on 2 May 2024, the company repurchased 3,201,647 shares during the week of 17 June 2024 up to and including 21 June 2024. The shares were repurchased at an average price of €15.66 for a total amount of €50,122,121.17. For detailed information on the daily repurchased shares, individual share purchase transactions and weekly reports, see the ING website at . In line with the purpose of the programme to reduce the share capital of ...
- Emmanuel Matot
- Jean-Baptiste Rouphael
- Jeremy Garnier
- Marc Lavaud
- Nicolas Thorez
ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 06/24/2024
Dutch real estate companies showed signs of cautious optimism at the recent Provada conference, with logistics and retail favoured. Healthcare shows some positive signs, with limited devaluations. The Dutch government's potential reduction of the Real Estate Transfer Tax and new REIT regime could benefit listed real estate companies active in the country. - ...
MC LVMH MOET HENNESSY LOUIS VUITTON SE
LI KLEPIERRE SA
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
ERIC B TELEFONAKTIEBOLAGET LM ERICSSON CLASS B
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
KER KERING SA
ISP INTESA SANPAOLO S.P.A.
01913 PRADA S.P.A.
SOI SOITEC SA
ELI ELIA GROUP SA/NV
UCG UNICREDIT S.P.A.
MONC MONCLER SPA
IBE IBERDROLA SA
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
RACE FERRARI NV
BHP BHP GROUP LTD
ARGX ARGEN-X SE
ULA UNIBAIL-RODAMCO-WESTFIELD SE STAPLED SECS CONS OF 1 SH UNIBAIL RODAMCO + 1 SH WFD UNIB ROD
- Bruno Cavalier
- Emmanuel Matot
- Jean-Baptiste Rouphael
- Jeremy Garnier
- Marc Lavaud
- Nicolas Thorez
ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 24/06/2024
Dutch real estate companies showed signs of cautious optimism at the recent Provada conference, with logistics and retail favoured. Healthcare shows some positive signs, with limited devaluations. The Dutch government's potential reduction of the Real Estate Transfer Tax and new REIT regime could benefit listed real estate companies active in the country. - ...
MC LVMH MOET HENNESSY LOUIS VUITTON SE
LI KLEPIERRE SA
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
ERIC B TELEFONAKTIEBOLAGET LM ERICSSON CLASS B
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
KER KERING SA
ISP INTESA SANPAOLO S.P.A.
01913 PRADA S.P.A.
SOI SOITEC SA
ELI ELIA GROUP SA/NV
UCG UNICREDIT S.P.A.
MONC MONCLER SPA
IBE IBERDROLA SA
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
RACE FERRARI NV
BHP BHP GROUP LTD
ARGX ARGEN-X SE
ULA UNIBAIL-RODAMCO-WESTFIELD SE STAPLED SECS CONS OF 1 SH UNIBAIL RODAMCO + 1 SH WFD UNIB ROD
- Damien Choplain
- Martial Descoutures
Argenx : Green light from the FDA for Vygart Hytrulo in CIDP
>Vyvgart Hytrulo approved in CIDP - Last Friday evening, Vyvgart Hytrulo (subcutaneous version of Vyvgart) obtained FDA approval for use in chronic inflammatory demyelinating polyneuropathy (CIDP), the second indication approved in the US after Myasthenia Gravis (MG). The product has been granted a broad label and can therefore be prescribed for all patients with CIDP and throughout the treatment algorithm, which we consider to be a best-case scenario. This approval i...
- Damien Choplain
- Martial Descoutures
Argenx : Feu vert de la FDA pour Vyvgart Hytrulo dans la CIDP
>Vyvgart Hytrulo approuvé dans la CIDP - Vendredi soir dernier Vyvgart Hytrulo (version sous-cutanée de Vyvgart) a obtenu l’approbation de la FDA pour une utilisation dans la polyneuropathie inflammatoire démyélinisante chronique (CIDP), deuxième indication approuvée aux US après la Myasthénie Grave (MG). Le produit a obtenu un label large et pourra donc être prescrit chez tous les patients atteints de CIDP et tout au long de l’algorithme de traitement, ce que nous co...
- Hilde Van Boxstael
- Thomas Vranken
- Wim Lewi
- Thomas Vranken
argenx CIDP joins the party
argenx meets and exceeds our expectations with a broad label approval for CIDP, the 2nd approved indication in the US, which unlocks Vyvgart regardless of prior therapies. Based on updated patient population estimates and a premium $ 450k net pricing, we upgrade our peak sales estimate from $ 3.05bn to $ 3.76bn and increase our TP to € 460 (previously € 420 while we reiterate our Buy rating.
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammat...
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy VYVGART® Hytrulo is first and only neonatal Fc receptor (FcRn) blocker approved to treat chronic inflammatory demyelinating polyneuropathy (CIDP) First novel, precision mechanism of action in more than 30 years for patients with CIDP Third approved indication for VYVGART® and VYVGART Hytrulo franchise Management to host conference call on June 21, 2024 at 11:00pm CET (5:00pm ET) June 21, 2024, 4:40pm ET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global imm...
- Guy Sips
- Hilde Van Boxstael
- Thomas Vranken
- Wim Lewi
- Thomas Vranken
argenx Preview on FDA's CIDP decision
CIDP could become the second marketed neuromuscular indication for efgartigimod in the US following gMG, pending expected FDA approval on June 21, 2024. In July 2023, argenx announced that it obtained positive topline data in its ADHERE study, featuring a 67% response rate in Stage A, and a primary endpoint hit in Stage B with a 61% reduction in risk of relapse versus placebo. We believe that efgartigimod could confer a treatment benefit over current treatment standards with sustained efficacy o...
- Jean Danjou
- Jean Danjou
- Thijs Berkelder
Ackermans & Van Haaren : Acquiring equity stake in ship manager V.Grou...
>Consortium led by STAR Capital acquires V.Group from Advent International - STAR Capital yesterday announced that its STAR IV Fund has signed an agreement to acquire V.Group, a global provider of mission critical services to the maritime industry. STAR will lead a consortium of investors including Ackermans & van Haaren and others to partner with V.Group’s management team. The transaction is subject to regulatory consents and is expected to complete in early autumn 2...
Progress on share buyback programme
Progress on share buyback programme Progress on share buyback programme ING announced today that, as part of our €2.5 billion share buyback programme announced on 2 May 2024, the company repurchased 3,163,163 shares during the week of 10 June 2024 up to and including 14 June 2024. The shares were repurchased at an average price of €16.85 for a total amount of €50,120,631.80. For detailed information on the daily repurchased shares, individual share purchase transactions and weekly reports, see the ING website at . In line with the purpose of the programme to reduce the share capital of ...
- Anthony Dick
- Bruno Cavalier
- Christophe-Raphaël Ganet
- Jean Danjou
- Marc Lavaud
ENGI ENGIE SA.
MC LVMH MOET HENNESSY LOUIS VUITTON SE
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
EL ESSILORLUXOTTICA SA
COLR ETABLISSEMENTEN FRANZ COLRUYT N.V.
BRBY BURBERRY GROUP PLC
KER KERING SA
01913 PRADA S.P.A.
MONC MONCLER SPA
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
INGA ING GROEP NV
ARGX ARGEN-X SE
NOVO B NOVO NORDISK A/S
- Anthony Dick
- Bruno Cavalier
- Jean Danjou
- Marc Lavaud
ENGI ENGIE SA.
MC LVMH MOET HENNESSY LOUIS VUITTON SE
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
EL ESSILORLUXOTTICA SA
COLR ETABLISSEMENTEN FRANZ COLRUYT N.V.
BRBY BURBERRY GROUP PLC
KER KERING SA
01913 PRADA S.P.A.
MONC MONCLER SPA
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
INGA ING GROEP NV
ARGX ARGEN-X SE
NOVO B NOVO NORDISK A/S
- ING Helpdesk
- Damien Choplain
- Martial Descoutures
Argenx : Negative phase II results in PC- POTS
>Discontinuation of programme in PC-POTS - Argenx announced negative results in the phase II ALPHA trial evaluating patients with post-Covid postural orthostatic tachycardia syndrome (PC-POTS). The study showed that the patients treated saw no clinically significant improvement relative to the placebo on the total score for Malmö POTS symptoms (MaPS) and COMPASS31 (the company provided no digital results). Argenx is to discontinue development of this indication a...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.